Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Alternext  >  ONCODESIGN    ALONC   FR0011766229

ONCODESIGN

(ALONC)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Alternext
07/07/2020 07/08/2020 07/09/2020 07/10/2020 07/13/2020 Date
12.35(c) 11.9(c) 12(c) 11.9(c) 11.65 Last
6 944 16 647 13 797 8 869 7 270 Volume
0.00% -3.64% +0.84% -0.83% -2.10% Change
More quotes
Financials
Sales 2020 36,1 M 40,9 M 40,9 M
Net income 2020 6,55 M 7,42 M 7,42 M
Net cash position 2020 7,65 M 8,66 M 8,66 M
P/E ratio 2020 12,4x
Yield 2020 -
Sales 2021 54,5 M 61,7 M 61,7 M
Net income 2021 15,5 M 17,6 M 17,6 M
Net cash position 2021 22,3 M 25,2 M 25,2 M
P/E ratio 2021 38,4x
Yield 2021 -
Capitalization 81,0 M 91,7 M 91,8 M
EV / Sales 2020 2,03x
EV / Sales 2021 1,08x
Nbr of Employees 233
Free-Float 50,4%
More Financials
Company
Oncodesign specializes in preclinical pharmacological evaluation services of new cancer therapies on behalf of the pharmaceutical and biotechnological companies. The group also provides research and development of drugs and biomarkers primarily for the treatment of cancer. France accounts for 60.7% of net sales. 
More about the company
Surperformance© ratings of ONCODESIGN
Trading Rating : Investor Rating :
More Ratings
Latest news on ONCODESIGN
05/25ONCODESIGN : and HitGen Announce a Strategic Partnership in Integrated Drug Disc..
BU
04/20ONCODESIGN : Announces the Creation of its new “Artificial Intelligence&rd..
BU
04/09ONCODESIGN : Very Strong Improvement in Full-Year 2019 Results
BU
04/09ONCODESIGN : Annual results
CO
04/07ONCODESIGN : to Host Conference Call Following the 2019 Full-Year Results Public..
BU
02/18ONCODESIGN : and Servier reach a key first milestone in their strategic partners..
AQ
02/17ONCODESIGN : and Servier Reach a Key First Milestone in Their Strategic Partners..
BU
01/20ONCODESIGN : Announces a 33% Revenue Increase in 2019 and the Achievement of Fin..
BU
01/20ONCODESIGN : 4th quarter earnings
CO
2019ONCODESIGN : Announces the Selection of Its First-in-Class RIPK2 Inhibitor Drug ..
BU
2019ONCODESIGN : Publication of an Article Presenting Promising Results for the Trea..
BU
2019ONCODESIGN : First-half 2019 results
PU
2019ONCODESIGN : First-half 2019 Results
BU
2019ONCODESIGN :  Acceleration in Growth in the First Half of 2019, With Sales Risin..
BU
2019ONCODESIGN : 2nd quarter earnings
CO
More news
News in other languages on ONCODESIGN
06/03ONCODESIGN : annonce la publication d'une étude d'initiation de couverture par P..
05/26EN DIRECT DES MARCHES : Sanofi, Renault, Scor, Vinci, Korian, Lufthansa, Siem..
05/26Wall Street et la City de retour
05/26Les valeurs à suivre aujourd'hui à la Bourse de Paris Mardi 26 mai 2020
05/25Les valeurs à suivre demain à la Bourse de Paris Mardi 26 mai 2020
More news
Chart ONCODESIGN
Duration : Period :
ONCODESIGN Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ONCODESIGN
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 16,13 €
Last Close Price 11,90 €
Spread / Highest target 68,1%
Spread / Average Target 35,5%
Spread / Lowest Target 3,36%
EPS Revisions
Managers
NameTitle
Philippe Genne Chairman & Chief Executive Officer
Jan Hoflack Chief Operating & Scientific Officer
Arnaud Lafforgue Chief Financial & Administrative Officer
Francis Bichat Director-Technology
Karine Lignel Director
Sector and Competitors
1st jan.Capitalization (M$)
ONCODESIGN23.70%92
LONZA GROUP52.43%42 546
CELLTRION, INC.79.28%36 149
SEATTLE GENETICS, INC.52.59%30 180
IQVIA HOLDINGS INC.-7.66%27 247
MODERNA, INC.220.09%24 344